Athi­ra’s al­ter­na­tive Alzheimer’s ap­proach runs in­to a PhII brick wall

Athi­ra Phar­ma re­port­ed an­oth­er set­back Wednes­day as its mid-stage Alzheimer’s study failed, be­com­ing the lat­est biotech to come up short in the dis­ease.

The Seat­tle …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER